A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-0122PMID 18981013PMCID PMC3543872
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• We should desist using RECIST, at least in GIST.

  2007cited by this paper
• Discovery and development of SAHA as an anticancer agent

  2007cited by this paper
• Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma

  2007cited by this paper
• Histone Deacetylase Inhibitors: Biology and Mechanism of Action

  2007cited by this paper
• Progression-specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas in situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis

  2006cited by this paper
• A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer

  2006cited by this paper
• Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.

  2006cited by this paper
• Histone Deacetylase Inhibitors: From Chromatin Remodelling to Experimental Cancer Therapeutics

  2005cited by this paper
• Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2

  2005cited by this paper
• Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

  2005cited by this paper
• Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.

  2004cited by this paper
• Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.

  2004cited by this paper
• The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen

  2004cited by this paper
• The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.

  2004cited by this paper
• Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

  2003cited by this paper
• Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics.

  2003cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• The fundamental role of epigenetic events in cancer

  2002cited by this paper
• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.

  2001cited by this paper
• Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

  1999cited by this paper
• Expression of hemidesmosomes and component proteins is lost by invasive breast cancer cells.

  1995cited by this paper

• The novel selective HDAC1 inhibitor ZJH-1 exhibits potent antitumor activity in castration-resistant prostate cancer, potentially involving HSP90AA1.

  2025cites this paper
• Precision epigenetic therapies in oncology

  2025cites this paper
• A promising future for breast cancer therapy with hydroxamic acid-based histone deacetylase inhibitors.

  2025cites this paper
• Histone acetylation modulators in breast cancer

  2025cites this paper
• BKS-112, a Selective Histone Deacetylase 6 Inhibitor, Suppresses Triple-Negative Breast Cancer Cells via AKT/mTOR Pathway

  2025cites this paper
• Advances in the epigenetic regulation of breast cancer

  2025cites this paper
• RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications

  2025cites this paper
• Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications

  2024cites this paper
• Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview

  2024cites this paper
• Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression

  2023cites this paper
• Recent advancement of HDAC inhibitors against breast cancer

  2023cites this paper
• A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma

  2023cites this paper
• Signaling pathways in cancer metabolism: mechanisms and therapeutic targets

  2023cites this paper
• Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories

  2023cites this paper
• Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells

  2023cites this paper
• Hedgehog pathway orchestrates the interplay of histone modifications and tailors combination epigenetic therapies in breast cancer

  2023cites this paper
• Epigenetic Therapies and Biomarkers in Breast Cancer

  2022cites this paper
• Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.

  2022cites this paper
• The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention

  2022cites this paper
• HDAC6 score: to treat or not to treat?

  2022cites this paper
• The epigenetics of breast cancer – Opportunities for diagnostics, risk stratification and therapy

  2021cites this paper
• Changes in the Expression of TBP-2 in Response to Histone Deacetylase Inhibitor Treatment in Human Endometrial Cells

  2021cites this paper
• Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.

  2021cites this paper
• Effect of the hydroxamate group in the antitumoral activity and toxicity toward normal cells of new copper(II) complexes

  2021cites this paper
• Vorinostat (SAHA) and Breast Cancer: An Overview

  2021cites this paper
• Recent Advances in Prodrug-based Nanoparticle Therapeutics.

  2021cites this paper
• Targeting Histone Modifications in Bone and Lung Metastatic Cancers

  2021cites this paper
• A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

  2021cites this paper
• Systemic Anticancer Agents

  2021cites this paper
• Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer

  2021cites this paper
• Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach

  2020cites this paper
• Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.

  2020cites this paper
• Bifunctional HDAC Therapeutics: One Drug to Rule Them All?

  2020cites this paper
• Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair

  2020cites this paper
• Targeting Cancer Stem Cells and Metastasis with Epigenetic Modulation and Anti-HER2 Therapy: Phase I/II Trial of Vorinostat in Combination with Lapatinib

  2020cites this paper
• Approaching Complex Diseases: Network-Based Pharmacology and Systems Approach in Bio-Medicine

  2020cites this paper
• Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.

  2020cites this paper
• Precision Oncology vs Phenotypic Approaches in the Management of Cancer: A Case for the Postmitotic State

  2020cites this paper
• 18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer

  2020cites this paper
• MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer

  2020cites this paper
• xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner

  2020cites this paper
• Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier

  2020cites this paper
• Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma

  2020cites this paper
• Beyond regulations at DNA levels: A review of epigenetic therapeutics targeting cancer stem cells

  2020cites this paper
• Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy

  2019cites this paper
• Perturbing Enhancer Activity in Cancer Therapy

  2019cites this paper
• Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia.

  2019cites this paper
• Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer

  2019cites this paper
• Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability

  2019cites this paper
• Small molecule HDAC inhibitors: Promising agents for breast cancer treatment.

  2019cites this paper
• Epigenetics in Metastatic Breast Cancer: Its Regulation and Implications in Diagnosis, Prognosis and Therapeutics.

  2019cites this paper
• Histone deacetylase inhibitor, AR‐42, exerts antitumor effects by inducing apoptosis and cell cycle arrest in Y79 cells

  2019cites this paper
• Lessons we can learn from neurons to make cancer cells quiescent

  2019influential citation
• Histone Deacetylase Inhibitors in Tumor Immunotherapy.

  2019cites this paper
• Key actors in cancer therapy: epigenetic modifiers

  2019cites this paper
• Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents.

  2019cites this paper
• p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death

  2019cites this paper
• Effects of SAHA and EGCG on Growth Potentiation of Triple-Negative Breast Cancer Cells

  2018cites this paper
• Investigation into the role of HER2 receptor signalling in Hypoxia-inducible Factor Regulation in breast cancer

  2018cites this paper
• Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53

  2018cites this paper
• Histone Deacetylase Inhibitors in Cancer

  2018cites this paper
• A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer

  2018cites this paper
• CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy

  2018cites this paper
• Self-Assembled Nanomicelles as Curcumin Drug Delivery Vehicles: Impact on Solitary Fibrous Tumor Cell Protein Expression and Viability.

  2018cites this paper
• Supramolecularly self-assembled nano-twin drug for reversing multidrug resistance.

  2018cites this paper
• Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine.

  2018cites this paper
• Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

  2018influential citation
• The emergence of specific HDAC inhibitors and their clinical efficacy in the treatment of hematologic malignancies and breast cancer

  2018cites this paper
• Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics

  2018cites this paper
• HDAC5–LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells

  2018cites this paper
• Optimizing poly (ADP‐ribose) polymerase inhibition through combined epigenetic and immunotherapy

  2018cites this paper
• HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR‐200c targeting CRKL

  2018cites this paper
• Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer.

  2018cites this paper
• Molecular mechanisms underlying the action of histone deacetylases inhibitors (HDACIs) in ovarian cancer

  2017cites this paper
• Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.

  2017cites this paper
• Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer

  2017cites this paper
• Transgenerational inheritance of increased breast cancer risk in mouse offspring of dams exposed to high fat N-6 polyunsaturated fatty acid diet during pregnancy

  2017cites this paper
• Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases

  2017cites this paper
• Epigenetics in cancer stem cells

  2017cites this paper
• Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.

  2017cites this paper
• Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.

  2017cites this paper
• A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)

  2017cites this paper
• Investigating c-FLIP suppression and TRAIL treatment in breast cancer

  2017cites this paper
• Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.

  2017cites this paper
• Clinical Applications of Histone Deacetylase Inhibitors

  2017cites this paper
• Mammalian SWI/SNF Enzymes and the Epigenetics of Tumor Cell Metabolic Reprogramming

  2017cites this paper
• Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers.

  2017cites this paper
• Functional Interaction of Histone Deacetylase 5 (HDAC5) and Lysine-specific Demethylase 1 (LSD1) Promotes Breast Cancer Progression

  2016cites this paper
• Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.

  2016cites this paper
• Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.

  2016cites this paper
• Epigenetic polypharmacology: from combination therapy to multitargeted drugs

  2016cites this paper
• NUMBER : W 81 XWH-14-1-0237 TITLE : Targeting Histone Abnormality in Triple-Negative Breast Cancer

  2016cites this paper
• Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer

  2016cites this paper
• Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma

  2016cites this paper
• Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer

  2016cites this paper
• Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals

  2016cites this paper
• Histone Deacetylase Inhibitors in Medical Therapeutics

  2016cites this paper
• Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy

  2016cites this paper
• Chapter 13 – Clinical Applications of Epigenetic Drugs

  2016cites this paper
• dbPHCC: The construction of a database of prognostic biomarkers and models for hepatocellular carcinoma

  2016cites this paper